Cord blood stem cells aim to tame transplant complication
NCT ID NCT03158896
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested whether stem cells from donated umbilical cords are safe for people with a serious condition called acute graft versus host disease (aGVHD), which can happen after a bone marrow transplant. Twenty-four adults received one of two doses of these stem cells. The main goal was to see if the treatment caused serious side effects, and researchers also looked for signs that it helped control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- umbilical cord stem cells (Wharton's jelly mesenchymal stem cells)
- What this could lead to
- If this works, it could point toward a new treatment option for a serious complication of bone marrow transplants, helping control the immune attack on the body.
- What could go wrong
- This is a very early, small phase 1 trial with only 24 people, so it is mainly checking safety, not effectiveness. The stem cells may not work, and there are risks of side effects from the infusion.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kansas University Cancer Center
Kansas City, Kansas, 66160, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a lung protein tame severe graft-versus-host disease?
- Combination drug approach aims to tame immune attack after stem cell transplant
- New shot may shield transplant patients from deadly immune attack
- New drug shows promise in controlling transplant complications
- Poop pills may tame deadly transplant complication
- JAKAVI under the microscope: new study tracks GVHD treatment in real life